The human papilloma virus testing market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 14.14% from 2025 to 2033. The market is fueled by rising HPV-related cancer cases, with human papilloma virus (HPV) causing over 95% of cervical cancers.
By product, the Consumables segment held the highest market share of 65.34% in 2024.
Based on technology, the PCR segment held the highest market share of 39.48% in 2024.
By application, the cervical cancer screening segment dominated the market with the largest revenue share of 76.7% in 2024.
By end use, the hospitals & clinics segment held the largest market share in 2024.
2024 Market Size: USD 1.76 Billion
2033 Projected Market Size: USD 5.67 Billion
CAGR (2025–2033): 14.14%
North America: Largest market in 2024
Asia Pacific: Fastest growing market
Countries like Australia have replaced Pap smears with HPV DNA testing for higher sensitivity. Self-sampling kits, such as those from BD and Hologic, are expanding access in underserved areas. WHO’s elimination strategy and NGO-backed programs in Africa and Asia drive adoption. Advances in molecular diagnostics, bundled women’s health panels, and improved lab infrastructure make testing more accessible and cost-effective globally. Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of female cancer-related mortality.
The degree of innovation in HPV NAATs is high, reflecting significant advancements in molecular diagnostics that have transformed cervical cancer screening. Platforms such as the Aptima HPV Assay introduced E6/E7 mRNA detection, improving specificity by targeting actively replicating virus rather than latent infections. Cepheid’s Xpert HPV brought true “near-patient” testing with rapid, cartridge-based E6/E7 DNA amplification on scalable GeneXpert modules, enabling on-demand results in under an hour. Seegene’s Anyplex II leverages proprietary TOCE™ technology to simultaneously genotype 14 to 28 HPV types with semi-quantitative viral load estimation in a single reaction. These innovations enhance accuracy, throughput, and clinical utility, supporting large-scale population screening and rapid diagnostic workflows.
The cervical cancer screening segment dominated the market with the largest revenue share of 76.7% in 2024 due to the high prevalence of HPV-related cervical cancer worldwide. Early detection through HPV testing is essential for preventing the progression of cervical cancer, driving widespread adoption of screening programs. The availability of advanced, noninvasive testing methods, such as HPV DNA tests and liquid-based cytology, has contributed to the segment growth. In addition, increasing awareness of cervical cancer prevention and government initiatives supporting regular screenings further boost demand for HPV testing in cervical cancer detection.
North America human papilloma virus testing market dominated the global market with the largest revenue share of 41.6% in 2024. The integration of HPV testing into routine checkups and the increase in preventive healthcare drive significant market growth. Routine screenings for HPV, especially in women, are becoming a standard part of preventive care, helping detect potential risks early. The rising focus on proactive healthcare and disease prevention, along with improved guidelines for cervical cancer screening, boosts the demand for HPV testing. Moreover, healthcare providers increasingly emphasize regular testing to identify high-risk strains, further expanding the market size.
Some key companies in the human papilloma virus testing industry include Abbott, bioMerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, and Siemens Healthineers AG.
Abbott offers innovative healthcare solutions, including diagnostic tools, medical devices, nutrition products, and branded generic medicines. The company focuses on improving health and enhancing lives through cutting-edge technology and scientifically backed solutions worldwide.
bioMérieux specializes in diagnostic solutions, offering a range of products and services for clinical microbiology, molecular biology, and immunoassays. Its solutions help detect infectious diseases, ensuring faster, more accurate diagnoses and better patient outcomes globally.
The following are the leading companies in the HPV testing market. These companies collectively hold the largest market share and dictate industry trends.
Abbott
Biomedical Diagnostics
bioMerieux
Bio-Rad Laboratories, Inc.
Fujirebio
Oncolab
Hologic, Inc.
Qiagen
F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
The FDA approval of Teal Wand, the first at-home cervical cancer screening test, marks a significant strategic milestone in women’s health. Targeting women aged 25–65, the test enables self-sampling at home with lab analysis and online results in under a week. Validated in a study of 600+ women, it demonstrated equivalent accuracy to clinician-collected samples, addressing barriers to clinic-based Pap smears. With a launch planned in California in June 2025, Teal Wand aims to expand screening access, improve early detection, and capture untapped market segments. This positions the company as an innovation leader while unlocking new revenue streams in preventive diagnostics.
Application Outlook (Revenue, USD Million, 2021–2033)
Cervical Cancer Screening
Vaginal Cancer Screening
Product Outlook (Revenue, USD Million, 2021–2033)
Instruments
Consumables
Services
Technology Outlook (Revenue, USD Million, 2021–2033)
PCR
Immunodiagnostics
Others
End Use Outlook (Revenue, USD Million, 2021–2033)
Hospitals & Clinics
Laboratories
Others